参考文献/References:
[1] Shah P L, Hansell D, Lawson P R, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis[J].Thorax,2000, 55(1):67-77.
[2] Seymour J F, Presneill J J. Pulmonary alveolar proteinosis: progress in the first 44 years [J].Am J Respir Crit Care Med,2002,166(2):215-235.
[3] Suzuki T, Trapnell B C. Pulmonary alveolar proteinosis syndrome[J].Clin Chest Med,2016, 37(3):431-440.
[4] Xu Z, Jing J, Wang H, et al. Pulmonary alveolar proteinosis in China: a systematic review of 241 cases[J].Respirology,2009,14(5):761-766.
[5] 徐凯峰,陈燕,郭子健,等.肺泡蛋白沉积症患者血清中抗粒-巨噬细胞集落刺激因子抗体等血清学指标的临床意义[J].中华结核和呼吸杂志,2004,27(12): 824-828.
[6] 李妍,田欣伦,桂耀松,等.自身免疫性肺泡蛋白沉积症血清脂代谢持点[J].中国医学科学院学报,2014,11(6):645-649.
[7] Inoue Y, Trapnell B C, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan[J].Am J Respir Crit Care Med, 2008, 177(7):752-762.
[8] Arai T, Inoue Y, Sugimoto C, et al. Cyfra 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis[J].Respirology,2014, 19(2):246-252.
[9]Campo I,Mariani F,Rodi G,et al.Assessment and management of pulmonary alveolar proteinosis in a reference center[J].Orphanel J Rare Dis,2013,45(8):40-45.
[10] Vercauteren I M,Verleden S E,McDonough J E,et a1.CYFRA 21-1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients[J].Exp Lung Res,2015,41(8):459-465.
[11] Long X, He X, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis[J].Eur Respir J,2017,49(2):459-465.
[12] Malur A, Baker A D, McCoy A J, et al. Restoration of PPARgamma reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice[J].Am J Physiol Lung Cell Mol Physiol,2011,30(1):73-80.